Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa

Eur J Dermatol. Sep-Oct 2012;22(5):640-4. doi: 10.1684/ejd.2012.1795.

Abstract

Hidradenitis suppurativa (HS) is a chronic suppurative disease impairing patients' quality of life (QOL). The standard treatment remains extensive surgery; medical treatment is often disappointing.

Objectives: Prolonged infliximab efficacy and tolerance in moderate-to-severe forms of HS were evaluated.

Patients and methods: This prospective, monocentric, open, interventional study concerned patients with progressive, moderate-to-severe HS ineligible for surgery, or who relapsed after surgery. Infliximab (5 mg/kg) was infused at weeks 0, 2 and 6, and then every 4 weeks. When the response was satisfactory, infusion spacing was attempted.

Results: Ten patients were included, 8 treated for 1 year, with a mean of 5 affected sites and 18 years of evolution. The mean initial DLQI was 20/30 (range 9-30). At 1 year, the number of involved sites (P<0.001) and flares (P<0.05) had decreased significantly under infliximab, as did HS severity. QOL improved clearly and rapidly for all patients, with mean DLQI at 6/30 (P<0.001). Tolerance was satisfactory with only 4 minor infections, 1 keratoacanthoma and one rapidly resolving hepatitis.

Conclusion: This evaluation of prolonged infliximab use in HS after surgical failure showed good efficacy and satisfactory tolerance without therapeutic escape during the first year of treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Quality of Life*
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Time Factors
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Infliximab